CN101977596A - 大麻素类的新用途 - Google Patents

大麻素类的新用途 Download PDF

Info

Publication number
CN101977596A
CN101977596A CN2009801103479A CN200980110347A CN101977596A CN 101977596 A CN101977596 A CN 101977596A CN 2009801103479 A CN2009801103479 A CN 2009801103479A CN 200980110347 A CN200980110347 A CN 200980110347A CN 101977596 A CN101977596 A CN 101977596A
Authority
CN
China
Prior art keywords
purposes
cbd
thcv
cannabinoid
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801103479A
Other languages
English (en)
Chinese (zh)
Inventor
G·盖伊
S·赖特
M·A·考索恩
S·奥萨利文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Publication of CN101977596A publication Critical patent/CN101977596A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pyrane Compounds (AREA)
CN2009801103479A 2008-01-21 2009-01-21 大麻素类的新用途 Pending CN101977596A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0801051.4 2008-01-21
GB0801051.4A GB2459637B (en) 2008-01-21 2008-01-21 New use for cannabinoids
PCT/GB2009/000159 WO2009093018A1 (en) 2008-01-21 2009-01-21 New use for cannabinoids

Publications (1)

Publication Number Publication Date
CN101977596A true CN101977596A (zh) 2011-02-16

Family

ID=39166091

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801103479A Pending CN101977596A (zh) 2008-01-21 2009-01-21 大麻素类的新用途

Country Status (8)

Country Link
US (2) US20110082195A1 (enExample)
EP (1) EP2254565A1 (enExample)
JP (2) JP2011509989A (enExample)
CN (1) CN101977596A (enExample)
BR (1) BRPI0906936A2 (enExample)
CA (1) CA2711873A1 (enExample)
GB (1) GB2459637B (enExample)
WO (1) WO2009093018A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103945841A (zh) * 2011-11-21 2014-07-23 Gw药品有限公司 用于保护胰岛细胞的四氢次大麻酚(thcv)
CN107846936A (zh) * 2015-07-22 2018-03-27 芙图法尔马国际有限公司 蜜蜂可摄取组成物及使用其生产蜂蜜的方法与由此生产的蜂蜜
WO2019232740A1 (zh) * 2018-06-07 2019-12-12 汉义生物科技（北京）有限公司 一种用于防治糖尿病的药物组合物及其用途
CN110575447A (zh) * 2018-06-07 2019-12-17 汉义生物科技（北京）有限公司 一种用于防治糖尿病的药物组合物及其用途
CN111417392A (zh) * 2017-10-18 2020-07-14 莫尔研究应用有限公司 大麻二酚和壳聚糖组合物及其使用方法
CN116744911A (zh) * 2020-11-23 2023-09-12 雀巢产品有限公司 作为ampk活化剂的取代的间苯二酚化合物、其组合物、方法和用途

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
CA2586358C (en) 2004-11-16 2015-11-24 Gw Pharma Limited Use of tetrahydrocannabivarin (thcv) as neutral antagonist of the cb1 cannabinoid receptor
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
CA2726085A1 (en) * 2010-12-20 2012-06-20 Bernard Le Foll User of marihuana and compounds therein for treating obesity
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9259449B2 (en) * 2014-01-07 2016-02-16 Joshua Michael Raderman Method for modifying THC content in a lipid-based extract of cannabis
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2527591A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd 7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
US9539295B2 (en) 2014-12-05 2017-01-10 Bradley Michael Bohus Cannabidiol (CBD) enriched alcohol
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
TWI753930B (zh) 2016-08-01 2022-02-01 德商矢倫德國股份有限公司 鏈條封閉鏈結
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
CA3077624A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
CA3091719A1 (en) * 2018-08-08 2020-02-13 Neptune Wellness Solutions Inc. Cold extraction method for cannabinoids and terpenes from cannabis by organic solvents
US12144795B2 (en) 2018-09-05 2024-11-19 Purisys Llc Cannabidiol compositions having modified cannabinoid profiles
WO2020240550A1 (en) * 2019-05-28 2020-12-03 Bol Pharma Ltd. Cannabidiol for treating type 1 diabetes mellitus
US20210015762A1 (en) * 2019-07-16 2021-01-21 TRUETIVA, Inc. Compositions for treating obesity
MX2022003189A (es) 2019-09-16 2022-06-08 Vapor Cartridge Tech Llc Sistema de administración de fármacos con sustratos apilables.
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
JP7670700B2 (ja) 2019-10-11 2025-04-30 パイク セラピューティクス インコーポレイテッド 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
WO2021074790A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
JP2021061789A (ja) * 2019-10-15 2021-04-22 サムライ金沢株式会社 食品組成物および飼料組成物
KR102448514B1 (ko) * 2019-12-10 2022-10-05 한국 한의학 연구원 대마 줄기 추출물을 유효성분으로 함유하는 동맥경화의 예방, 개선 또는 치료용 조성물
IL272078A (en) 2020-01-16 2021-07-29 Can Fite Biopharma Ltd Cannabinoids for use in treatment
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
KR102393416B1 (ko) * 2020-06-04 2022-05-02 재단법인 경북바이오산업연구원 대마 뿌리 추출물을 포함하는 항당뇨용 조성물
KR102393417B1 (ko) * 2020-06-04 2022-05-02 재단법인 경북바이오산업연구원 대마 줄기 추출물을 포함하는 항당뇨용 조성물
KR20210158175A (ko) * 2020-06-23 2021-12-30 주식회사 유셀파마 대마 줄기 추출물을 유효성분으로 함유하는 고콜레스테롤혈증의 예방, 개선 또는 치료용 조성물
EP4188090A4 (en) 2020-07-28 2024-08-14 Impello Biosciences, Inc. METHODS AND COMPOSITIONS FOR MODIFYING SECONDARY METABOLITES IN PLANTS
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US20240082269A1 (en) * 2022-04-20 2024-03-14 Gregory L. Smith Methods and products including specific cannabinoids

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381194A (en) * 2001-09-07 2003-04-30 Gw Pharmaceuticals Ltd Pharmaceutical formulations
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
CA2586358C (en) * 2004-11-16 2015-11-24 Gw Pharma Limited Use of tetrahydrocannabivarin (thcv) as neutral antagonist of the cb1 cannabinoid receptor
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
EP2007376B1 (en) * 2006-03-13 2013-05-08 Hadasit Medical Research Services And Development Ltd. Therapeutic uses of cannabidiol compounds
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
WO2008031439A2 (en) * 2006-09-15 2008-03-20 Stevia Aps Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo [ 3.2. i ]octans such as steviol and isosteviol
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103945841A (zh) * 2011-11-21 2014-07-23 Gw药品有限公司 用于保护胰岛细胞的四氢次大麻酚(thcv)
US11426434B2 (en) 2015-07-22 2022-08-30 Phytopharma International Ltd. Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
CN107846936A (zh) * 2015-07-22 2018-03-27 芙图法尔马国际有限公司 蜜蜂可摄取组成物及使用其生产蜂蜜的方法与由此生产的蜂蜜
CN107846936B (zh) * 2015-07-22 2021-06-01 芙图法尔马国际有限公司 蜜蜂可摄取组成物及使用其生产蜂蜜的方法与由此生产的蜂蜜
US12233044B2 (en) 2017-10-18 2025-02-25 Mor Research Applications Ltd. Cannabidiol and chitosan compositions and methods of using the same
CN111417392A (zh) * 2017-10-18 2020-07-14 莫尔研究应用有限公司 大麻二酚和壳聚糖组合物及其使用方法
US11679094B2 (en) 2017-10-18 2023-06-20 Mor Research Applications Ltd. Cannabidiol and chitosan compositions and methods of using the same
CN110575447A (zh) * 2018-06-07 2019-12-17 汉义生物科技（北京）有限公司 一种用于防治糖尿病的药物组合物及其用途
CN110575447B (zh) * 2018-06-07 2022-11-29 汉义生物科技（北京）有限公司 一种用于防治糖尿病的药物组合物及其用途
JP2021520403A (ja) * 2018-06-07 2021-08-19 漢義生物科技（北京）有限公司 糖尿病予防・治療用の医薬品組成物及びその用途
JP7344422B2 (ja) 2018-06-07 2023-09-14 漢義生物科技（北京）有限公司 糖尿病予防・治療用の医薬品組成物及びその用途
WO2019232740A1 (zh) * 2018-06-07 2019-12-12 汉义生物科技（北京）有限公司 一种用于防治糖尿病的药物组合物及其用途
CN116744911A (zh) * 2020-11-23 2023-09-12 雀巢产品有限公司 作为ampk活化剂的取代的间苯二酚化合物、其组合物、方法和用途

Also Published As

Publication number Publication date
JP2011509989A (ja) 2011-03-31
GB2459637B (en) 2012-06-06
US20110082195A1 (en) 2011-04-07
EP2254565A1 (en) 2010-12-01
JP2015120739A (ja) 2015-07-02
WO2009093018A1 (en) 2009-07-30
GB0801051D0 (en) 2008-02-27
GB2459637A (en) 2009-11-04
US20130245110A1 (en) 2013-09-19
CA2711873A1 (en) 2009-07-30
BRPI0906936A2 (pt) 2015-07-28

Similar Documents

Publication Publication Date Title
CN101977596A (zh) 大麻素类的新用途
Yang et al. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation
Shen et al. Genistein ameliorated obesity accompanied with adipose tissue browning and attenuation of hepatic lipogenesis in ovariectomized rats with high-fat diet
US9573919B2 (en) Peroxisome proliferator-activated receptor (PPAR) activator, and drugs, supplements, functional foods and food additives using the same
Cao et al. Hydroxytyrosol prevents diet-induced metabolic syndrome and attenuates mitochondrial abnormalities in obese mice
Huang et al. Arctigenin, a natural compound, activates AMP-activated protein kinase via inhibition of mitochondria complex I and ameliorates metabolic disorders in ob/ob mice
Feng et al. Mitochondrial dynamic remodeling in strenuous exercise-induced muscle and mitochondrial dysfunction: regulatory effects of hydroxytyrosol
Li et al. Butyrate alleviates metabolic impairments and protects pancreatic β cell function in pregnant mice with obesity
de Theije et al. Distinct responses of protein turnover regulatory pathways in hypoxia-and semistarvation-induced muscle atrophy
Santos et al. Açaí seed extract prevents the renin-angiotensin system activation, oxidative stress and inflammation in white adipose tissue of high-fat diet–fed mice
CA2555296A1 (en) Composition of labdane diterpenes extracted from andrographis paniculata, useful for the treatment of autoimmune diseases, and alzheimer disease by activation of ppr-gamma receptors
Balaha et al. Phloretin either alone or in combination with duloxetine alleviates the STZ-induced diabetic neuropathy in rats
Hou et al. Effect of Sanguis draxonis (a Chinese traditional herb) on the formation of insulin resistance in rats
Zhou et al. Protection of trigonelline on experimental diabetic peripheral neuropathy
Gao et al. The role of adipose TRP channels in the pathogenesis of obesity
Yun et al. Aronia upregulates myogenic differentiation and augments muscle mass and function through muscle metabolism
Raoofi et al. Therapeutic potentials of the caffeine in polycystic ovary syndrome in a rat model: Via modulation of proinflammatory cytokines and antioxidant activity
EP2334377B1 (en) Herbal extract as sensitivity enhancer toward insulin and antidiabetes
Yan et al. The synergistic protective effects of paeoniflorin and β-ecdysterone against cardiac hypertrophy through suppressing oxidative stress and ferroptosis
TW201138798A (en) Use of sweet potato trypsin inhibitor for treating inflammation and hyperalgesia
Wang et al. Investigation of the role and mechanism of dapagliflozin in mitigating renal injury in rats afflicted with diabetic kidney disease
TWI489981B (zh) 使用茉莉酸治療膀胱功能障礙
Santos et al. The triterpenoid alpha, beta-amyrin prevents the impaired aortic vascular reactivity in high-fat diet-induced obese mice
JP5435951B2 (ja) コリナンテ種の樹皮からの抽出物、その使用、およびそれを含有する薬剤、ダイエット食品および医薬品
JP2009518429A (ja) 代謝症候群および糖尿病の治療のための抗炎症植物産物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20110216

RJ01 Rejection of invention patent application after publication